Avadel Pharmaceuticals PLC
AVDL21.690USD
+0.090+0.42%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
2.11BCap. mercado
PérdidaP/E TTM
Más Datos de Avadel Pharmaceuticals PLC Compañía
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Información de Avadel Pharmaceuticals PLC
Símbolo de cotizaciónAVDL
Nombre de la empresaAvadel Pharmaceuticals PLC
Fecha de salida a bolsaFeb 21, 2088
Director ejecutivoDivis (Gregory J)
Número de empleados188
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 21
DirecciónBlock 10-1 Blanchardstown Corporate Park
CiudadDUBLIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIreland
Código postal15
Teléfono35319015201
Sitio Webhttps://www.avadel.com/
Símbolo de cotizaciónAVDL
Fecha de salida a bolsaFeb 21, 2088
Director ejecutivoDivis (Gregory J)
Ejecutivos de Avadel Pharmaceuticals PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Eric J. Ende, M.D.
Dr. Eric J. Ende, M.D.
Independent Director
Independent Director
219.90K
--
Mr. Peter J. Thornton
Mr. Peter J. Thornton
Independent Director
Independent Director
115.06K
--
Ms. Linda S. Palczuk
Ms. Linda S. Palczuk
Independent Director
Independent Director
78.90K
--
Mr. Gregory J. (Greg) Divis, Jr.
Mr. Gregory J. (Greg) Divis, Jr.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Thomas S. Mchugh
Mr. Thomas S. Mchugh
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Geoffrey M. Glass
Mr. Geoffrey M. Glass
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Courtney Turiano
Ms. Courtney Turiano
Investor Relations
Investor Relations
--
--
Dr. Naseem Amin, M.D.
Dr. Naseem Amin, M.D.
Independent Director
Independent Director
--
--
Mr. Jerad Seurer
Mr. Jerad Seurer
General Counsel and Corporate Secretary
General Counsel and Corporate Secretary
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Eric J. Ende, M.D.
Dr. Eric J. Ende, M.D.
Independent Director
Independent Director
219.90K
--
Mr. Peter J. Thornton
Mr. Peter J. Thornton
Independent Director
Independent Director
115.06K
--
Ms. Linda S. Palczuk
Ms. Linda S. Palczuk
Independent Director
Independent Director
78.90K
--
Mr. Gregory J. (Greg) Divis, Jr.
Mr. Gregory J. (Greg) Divis, Jr.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Thomas S. Mchugh
Mr. Thomas S. Mchugh
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 3 de mar
Divisa: USDActualizado: lun., 3 de mar
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Vazculep
10.43M
46.70%
Akovaz
9.54M
42.74%
Bloxiverz
2.20M
9.85%
Other
159.00K
0.71%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
22.33M
100.00%
Ireland
0.00
0.00%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Vazculep
10.43M
46.70%
Akovaz
9.54M
42.74%
Bloxiverz
2.20M
9.85%
Other
159.00K
0.71%
Estadísticas de accionistas
Actualizado: dom., 11 de ene
Actualizado: dom., 11 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Janus Henderson Investors
7.57%
BlackRock Institutional Trust Company, N.A.
6.26%
The Vanguard Group, Inc.
5.91%
Brandes Investment Partners, L.P.
5.55%
Two Seas Capital LP
5.47%
Otro
69.24%
Accionistas
Accionistas
Proporción
Janus Henderson Investors
7.57%
BlackRock Institutional Trust Company, N.A.
6.26%
The Vanguard Group, Inc.
5.91%
Brandes Investment Partners, L.P.
5.55%
Two Seas Capital LP
5.47%
Otro
69.24%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
34.33%
Investment Advisor
31.96%
Hedge Fund
22.84%
Research Firm
4.62%
Venture Capital
3.46%
Individual Investor
1.06%
Bank and Trust
0.84%
Pension Fund
0.48%
Insurance Company
0.03%
Otro
0.39%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
402
92.83M
119.15%
+3.65M
2025Q3
398
82.11M
112.88%
-1.35M
2025Q2
383
83.11M
109.34%
+2.70M
2025Q1
369
80.46M
107.15%
-23.08M
2024Q4
346
82.09M
100.78%
+4.35M
2024Q3
324
77.51M
94.69%
+670.00K
2024Q2
289
76.58M
80.85%
+4.27M
2024Q1
248
72.03M
68.66%
+6.05M
2023Q4
216
57.48M
70.10%
+1.83M
2023Q3
210
56.27M
69.82%
+253.21K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Janus Henderson Investors
7.43M
7.64%
-3.70M
-33.26%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
6.15M
6.26%
+168.04K
+2.81%
Sep 30, 2025
The Vanguard Group, Inc.
5.86M
5.98%
+285.92K
+5.13%
Dec 31, 2025
Brandes Investment Partners, L.P.
5.44M
5.55%
-1.04M
-16.07%
Sep 30, 2025
Two Seas Capital LP
5.37M
5.47%
-785.99K
-12.77%
Sep 30, 2025
Tontine Asset Management, LLC
5.31M
5.41%
+138.20K
+2.67%
Sep 30, 2025
TIG Advisors, L.L.C.
3.86M
3.93%
+384.67K
+11.07%
Dec 23, 2025
Polar Capital LLP
4.00M
4.07%
--
--
Sep 30, 2025
Highbridge Capital Management, LLC
2.05M
2.09%
+751.06K
+57.88%
Dec 12, 2025
Vivo Capital, LLC
2.68M
2.73%
--
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Innovator IBD 50 Fund ETF
3.77%
Invesco Pharmaceuticals ETF
3.4%
iShares Neuroscience and Healthcare ETF
3.21%
ProShares Merger ETF
2.82%
State Street SPDR S&P Pharmaceuticals ETF
2.44%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.39%
AltShares Event-Driven ETF
1.21%
First Trust Small Cap Growth AlphaDEX Fund
1.02%
iShares U.S. Pharmaceuticals ETF
0.68%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.4%
Ver más
Innovator IBD 50 Fund ETF
Proporción3.77%
Invesco Pharmaceuticals ETF
Proporción3.4%
iShares Neuroscience and Healthcare ETF
Proporción3.21%
ProShares Merger ETF
Proporción2.82%
State Street SPDR S&P Pharmaceuticals ETF
Proporción2.44%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción2.39%
AltShares Event-Driven ETF
Proporción1.21%
First Trust Small Cap Growth AlphaDEX Fund
Proporción1.02%
iShares U.S. Pharmaceuticals ETF
Proporción0.68%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proporción0.4%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
